Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

NCT: NCT06710223 · ACTIVE_NOT_RECRUITING

NCT IDNCT06710223
StatusACTIVE_NOT_RECRUITING
Start Date2025-01-03
SponsorUniversity of California, San Diego (OTHER)
First posted
Last updated

Brief Summary

The goal of this Phase 1b clinical trial is to evaluate the safety and efficacy of cryoablation and hepatic arterial administration of SD-101 in participants with advanced hepatocellular carcinoma. After this procedure, participants will be treated with tremelimumab and durvalumab every 4 weeks (STRIDE regimen).

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑